Zoetis (NYSE:ZTS) Stock Sale Reported by Rep. Byron Donalds

Zoetis logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Rep. Byron Donalds disclosed selling $1,001–$15,000 of Zoetis shares on October 2 from his “MORAN WEALTH IRA” account.
  • Zoetis beat quarterly earnings expectations, reporting EPS of $1.75 versus $1.51 expected and revenue of $2.39 billion versus $2.30 billion expected; revenue was down 1.3% year over year.
  • The company announced a quarterly dividend of $0.53 per share, equivalent to a 2.5% annualized yield. Analysts’ consensus rating was “Hold,” with an average price target of $101.25.
  • Interested in Zoetis? Here are five stocks we like better.

Representative Byron Donalds (Republican-Florida) recently sold shares of Zoetis Inc. NYSE: ZTS. In a filing disclosed on November 16th, the Representative disclosed that they had sold between $1,001 and $15,000 in Zoetis stock on October 2nd. The trade occurred in the Representative's "MORAN WEALTH IRA" account.

Representative Byron Donalds also recently made the following trade(s):

  • Purchased $1,001 - $15,000 in shares of Interactive Brokers Group NASDAQ: IBKR on 10/2/2026.
  • Sold $1,001 - $15,000 in shares of Autodesk NASDAQ: ADSK on 10/2/2026.
  • Sold $1,001 - $15,000 in shares of Netflix NASDAQ: NFLX on 10/2/2026.

Zoetis Trading Down 1.3%

Shares of NYSE:ZTS opened at $83.32 on Wednesday. The stock has a market capitalization of $33.85 billion, a price-to-earnings ratio of 12.73, a PEG ratio of 1.22 and a beta of 0.67. The company has a debt-to-equity ratio of 2.51, a quick ratio of 1.40 and a current ratio of 2.35. The stock's 50-day simple moving average is $76.64 and its two-hundred day simple moving average is $91.18. Zoetis Inc. has a 52-week low of $68.77 and a 52-week high of $132.49.

Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The company reported $1.75 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.51 by $0.24. Zoetis had a return on equity of 85.90% and a net margin of 26.15%. The business had revenue of $2.39 billion during the quarter, compared to the consensus estimate of $2.30 billion. During the same period in the previous year, the company posted $1.70 EPS. The business's quarterly revenue was down 1.3% compared to the same quarter last year. Analysts expect that Zoetis Inc. will post 6.29 EPS for the current year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 1st. Shareholders of record on Friday, October 30th will be given a $0.53 dividend. This represents a $2.12 annualized dividend and a yield of 2.5%. The ex-dividend date of this dividend is Friday, October 30th. Zoetis's dividend payout ratio (DPR) is presently 36.05%.

Hedge Funds Weigh In On Zoetis

Several hedge funds have recently modified their holdings of the stock. Flossbach Von Storch SE acquired a new stake in Zoetis during the 2nd quarter worth $302,601,000. BlackRock Inc. lifted its stake in shares of Zoetis by 10.8% in the 2nd quarter. BlackRock Inc. now owns 39,430,181 shares of the company's stock valued at $2,833,453,000 after purchasing an additional 3,845,869 shares during the period. Ruane Cunniff & Goldfarb L.P. acquired a new position in shares of Zoetis in the 1st quarter valued at $286,660,000. Southpoint Capital Advisors LP lifted its stake in shares of Zoetis by 340.0% in the 1st quarter. Southpoint Capital Advisors LP now owns 2,200,000 shares of the company's stock valued at $260,062,000 after purchasing an additional 1,700,000 shares during the period. Finally, Carmignac Gestion bought a new position in shares of Zoetis in the 2nd quarter worth $113,230,000. Institutional investors and hedge funds own 92.80% of the company's stock.

Analysts Set New Price Targets

A number of research firms have issued reports on ZTS. Piper Sandler reduced their price objective on Zoetis from $90.00 to $80.00 and set a "neutral" rating on the stock in a research note on Monday, August 10th. Weiss Ratings upgraded shares of Zoetis from a "sell (d)" rating to a "sell (d+)" rating in a research report on Thursday, October 29th. The Goldman Sachs Group began coverage on shares of Zoetis in a research report on Friday, October 16th. They set a "neutral" rating and a $74.00 target price on the stock. BNP Paribas Exane decreased their target price on shares of Zoetis from $146.00 to $110.00 and set an "outperform" rating on the stock in a research report on Tuesday, August 11th. Finally, Cantor Fitzgerald set a $94.00 price target on shares of Zoetis in a report on Tuesday, August 25th. Eight equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of "Hold" and an average price target of $101.25.

Check Out Our Latest Stock Analysis on ZTS

About Representative Donalds

Byron Donalds (Republican Party) is a member of the U.S. House, representing Florida's 19th Congressional District. He assumed office on January 3, 2021. His current term ends on January 3, 2027. Donalds (Republican Party) is running for re-election to the U.S. House to represent Florida's 19th Congressional District. He declared candidacy for the 2026 election. Byron Donalds was born in Brooklyn, New York, and lives in Naples, Florida. Donalds earned a bachelor's degree in finance and marketing from Florida State University in 2002. His career experience includes working as a commercial credit officer in banking and as a portfolio manager in financial services.

About Zoetis

(Get Free Report)

Zoetis is an animal health company that discovers, develops, manufactures and markets medicines, vaccines, diagnostic products and other services for animals. Its products support both companion animals, such as dogs and cats, and livestock, including cattle, pigs, poultry, sheep and fish. The company's offerings include treatments for pain, infections and skin conditions, as well as vaccines, parasiticides, diagnostic tools and genetic testing services. Zoetis serves veterinarians, livestock producers and other animal health professionals around the world.

Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Zoetis Right Now?

Before you consider Zoetis, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zoetis wasn't on the list.

While Zoetis currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines